Research programme: KAT6A inhibitors - Isosterix
Latest Information Update: 27 Feb 2024
At a glance
- Originator Isosterix
- Class Antineoplastics; Small molecules
- Mechanism of Action KAT6A protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical HER2 negative breast cancer
Most Recent Events
- 27 Feb 2024 Research programme: KAT6A inhibitors - Isosterix is available for licensing as of 27 Feb 2024.
- 03 Dec 2023 Preclinical trials in HER2-negative-breast-cancer in USA (PO) prior to December 2023
- 05 Nov 2023 Pharmacokinetics and pharmacodynamics data from preclinical studies in HER2-negative-breast-cancer presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)